Cancer immunotherapy efficacy and machine learning

References

• Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309–5337. doi: 10.1016/j.cell.2021.09.020
   PubMed Web of Science ®Google Scholar
• Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261–267. doi: 10.1016/j.coi.2013.03.004
   PubMed Web of Science ®Google Scholar
• Xu Z, Wang X, Zeng S, et al. Applying artificial intelligence for cancer immunotherapy. Acta Pharm Sin B. 2021;11(11):3393–3405. doi: 10.1016/j.apsb.2021.02.007
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi: 10.1158/2159-8290.CD-21-1059
   PubMed Web of Science ®Google Scholar
• Bhalla S, Lagana A. Artificial intelligence for precision oncology. Adv Exp Med Biol. 2022;1361:249–268.
   PubMedGoogle Scholar
• Yu Y, Zeng D, Ou Q, et al. Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis. JAMA Netw Open. 2019;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879
   PubMed Web of Science ®Google Scholar
• Kang CY, Duarte SE, Kim HS, et al. Artificial intelligence-based radiomics in the era of immuno-oncology. Oncology. 2022;27(6):e471–e83. doi: 10.1093/oncolo/oyac036
   Google Scholar
• Yang Y, Yang J, Shen L, et al. A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. Am J Transl Res. 2021;13(2):743–756.
   PubMed Web of Science ®Google Scholar
• Chen ZH, Lin L, Wu CF, et al. Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. Cancer Commun (Lond). 2021;41(11):1100–1115. doi: 10.1002/cac2.12215
   PubMed Web of Science ®Google Scholar
• Dercle L, Zhao B, Gonen M, et al. Early readout on overall survival of patients with melanoma treated with immunotherapy using a novel imaging analysis. JAMA Oncol. 2022;8(3):385–392. doi: 10.1001/jamaoncol.2021.6818
   PubMed Web of Science ®Google Scholar
• Nishino M, Hatabu H, Johnson BE, et al. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology. 2014;271(1):6–27. doi: 10.1148/radiol.14122524
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420. doi: 10.1158/1078-0432.CCR-09-1624
   PubMed Web of Science ®Google Scholar
• Bohnsack O, Hoos A, Ludajic K. Adaptation of the immune related response criteria: irRECIST. Ann Oncol. 2014;25:iv369. doi: 10.1093/annonc/mdu342.23
   Google Scholar
• Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e52. doi: 10.1016/S1470-2045(17)30074-8
   PubMed Web of Science ®Google Scholar
• Hodi FS, Ballinger M, Lyons B, et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018;36(9):850–8. doi: 10.1200/JCO.2017.75.1644
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1(Suppl 1):122S–150S. doi: 10.2967/jnumed.108.057307
   PubMedGoogle Scholar
• Anwar H, Sachpekidis C, Winkler J, et al. Absolute number of new lesions on (18)F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45(3):376–383. doi: 10.1007/s00259-017-3870-6
   PubMed Web of Science ®Google Scholar
• Ito K, Teng R, Schoder H, et al. (18)F-FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. J Nucl Med. 2019;60(3):335–341. doi: 10.2967/jnumed.118.213652
   PubMed Web of Science ®Google Scholar
• Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489–2496. doi: 10.1182/blood-2016-05-718528
   PubMed Web of Science ®Google Scholar
• Cohen R, Bennouna J, Meurisse A, et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. J Immunother Cancer. 2020;8(2):e001499. doi: 10.1136/jitc-2020-001499
   PubMed Web of Science ®Google Scholar
• Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38–47. doi: 10.1016/j.ejca.2017.10.017
   PubMed Web of Science ®Google Scholar
• Castello A, Rossi S, Toschi L, et al. Comparison of metabolic and morphological response criteria for early prediction of response and survival in NSCLC patients treated with anti-PD-1/PD-L1. Front Oncol. 2020;10:1090. doi: 10.3389/fonc.2020.01090
   PubMed Web of Science ®Google Scholar
• Beer L, Hochmair M, Haug AR, et al. Comparison of RECIST, iRECIST, and PERCIST for the evaluation of response to PD-1/PD-L1 blockade therapy in patients with non-small cell lung cancer. Clin Nucl Med. 2019;44(7):535–543. doi: 10.1097/RLU.0000000000002603
   PubMed Web of Science ®Google Scholar
• Manitz J, D’Angelo SP, Apolo AB, et al. Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. J Immunother Cancer. 2022;10(2):e003302. doi: 10.1136/jitc-2021-003302
   PubMed Web of Science ®Google Scholar
• He B, Dong D, She Y, et al. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. J Immunother Cancer. 2020;8(2):e000550. doi: 10.1136/jitc-2020-000550
   PubMed Web of Science ®Google Scholar
• Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol. 2016;61(13):R150–R166. doi: 10.1088/0031-9155/61/13/R150
   PubMed Web of Science ®Google Scholar
• Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180–1191. doi: 10.1016/S1470-2045(18)30413-3
   PubMed Web of Science ®Google Scholar
• Avanzo M, Wei L, Stancanello J, et al. Machine and deep learning methods for radiomics. Med Phys. 2020;47(5):e185–e202. doi: 10.1002/mp.13678
   PubMed Web of Science ®Google Scholar
• George E, Flagg E, Chang K, et al. Radiomics-based machine learning for outcome prediction in a multicenter phase II study of programmed death-ligand 1 inhibition immunotherapy for glioblastoma. AJNR Am J Neuroradiol. 2022;43(5):675–681. doi: 10.3174/ajnr.A7488
   PubMed Web of Science ®Google Scholar
• Mu W, Tunali I, Gray JE, et al. Radiomics of (18)F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. Eur J Nucl Med Mol Imaging. 2020;47(5):1168–1182. doi: 10.1007/s00259-019-04625-9
   PubMed Web of Science ®Google Scholar
• Mu W, Katsoulakis E, Whelan CJ, et al. Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors. Br J Cancer. 2021;125(2):229–239. doi: 10.1038/s41416-021-01375-0
   PubMed Web of Science ®Google Scholar
• Gong J, Bao X, Wang T, et al. A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer. Oncoimmunology. 2022;11(1):2028962. doi: 10.1080/2162402X.2022.2028962
   PubMed Web of Science ®Google Scholar
• Khorrami M, Prasanna P, Gupta A, et al. Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer. Cancer Immunol Res. 2020;8(1):108–119. doi: 10.1158/2326-6066.CIR-19-0476
   PubMed Web of Science ®Google Scholar
• Wang C, Ma J, Shao J, et al. Non-invasive measurement using deep learning algorithm based on multi-source features fusion to predict PD-L1 expression and survival in NSCLC. Front Immunol. 2022;13:828560. doi: 10.3389/fimmu.2022.828560
   PubMed Web of Science ®Google Scholar
• Mu W, Jiang L, Shi Y, et al. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. J Immunother Cancer. 2021;9(6):e002118. doi: 10.1136/jitc-2020-002118
   PubMed Web of Science ®Google Scholar
• Tian P, He B, Mu W, et al. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. Theranostics. 2021;11(5):2098–2107. doi: 10.7150/thno.48027
   PubMed Web of Science ®Google Scholar
• Peeken JC, Asadpour R, Specht K, et al. MRI-based delta-radiomics predicts pathologic complete response in high-grade soft-tissue sarcoma patients treated with neoadjuvant therapy. Radiother Oncol. 2021;164:73–82. doi: 10.1016/j.radonc.2021.08.023
   PubMed Web of Science ®Google Scholar
• Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. ImmunoTher. Cancer 2019;7(1). doi: 10.1186/s40425-019-0768-9
   Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501. doi: 10.1056/NEJMc1713444
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi: 10.1093/annonc/mdy495
   PubMed Web of Science ®Google Scholar
• Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232–1243. doi: 10.1093/annonc/mdz116
   PubMed Web of Science ®Google Scholar
• Hause RJ, Pritchard CC, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types. Nature Med. 2016;22(11):1342–1350. doi: 10.1038/nm.4191
   PubMed Web of Science ®Google Scholar
• Zito Marino F, Ascierto PA, Rossi G, et al. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? Expert Opin Biol Ther. 2017;17(6):735–746. doi: 10.1080/14712598.2017.1309387
   PubMed Web of Science ®Google Scholar
• He Y, Rozeboom L, Rivard CJ, et al. PD-1, PD-L1 protein expression in non-small cell lung cancer and their relationship with Tumor-Infiltrating Lymphocytes. Med Sci Monit. 2017;23:1208–1216. doi: 10.12659/MSM.899909
   PubMed Web of Science ®Google Scholar
• Liu J, Geng R, Ni S, et al. Pyroptosis-related lncRnas are potential biomarkers for predicting prognoses and immune responses in patients with UCEC. Mol Ther Nucleic Acids. 2022;27:1036–1055. doi: 10.1016/j.omtn.2022.01.018
   PubMedGoogle Scholar
• McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463–1469. doi: 10.1126/science.aaf1490
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi: 10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104. doi: 10.1056/NEJMoa1801946
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940. doi: 10.1172/JCI91190
   PubMed Web of Science ®Google Scholar
• Sobhani F, Robinson R, Hamidinekoo A, et al. Artificial intelligence and digital pathology: opportunities and implications for immuno-oncology. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188520. doi: 10.1016/j.bbcan.2021.188520
   PubMed Web of Science ®Google Scholar
• Turkki R, Linder N, Kovanen PE, et al. Antibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples. J Pathol Inform. 2016;7(1):38. doi: 10.4103/2153-3539.189703
   PubMedGoogle Scholar
• Effland A, Kobler E, Brandenburg A, et al. Joint reconstruction and classification of tumor cells and cell interactions in melanoma tissue sections with synthesized training data. Int J Comput Assist Radiol Surg. 2019;14(4):587–599. doi: 10.1007/s11548-019-01919-z
   PubMed Web of Science ®Google Scholar
• Johannet P, Coudray N, Donnelly DM, et al. Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma. Clin Cancer Res. 2021;27(1):131–140. doi: 10.1158/1078-0432.CCR-20-2415
   PubMedGoogle Scholar
• Wang X, Barrera C, Bera K, et al. Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. Sci Adv. 2022;8(22):eabn3966. doi: 10.1126/sciadv.abn3966
   PubMed Web of Science ®Google Scholar
• Madabhushi A, Lee G. Image analysis and machine learning in digital pathology: challenges and opportunities. Med Image Anal. 2016;33:170–175.
   PubMed Web of Science ®Google Scholar
• Xu Y, Su GH, Ma D, et al. Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. Signal Transduct Target Ther. 2021;6(1):312. doi: 10.1038/s41392-021-00729-7
   PubMed Web of Science ®Google Scholar
• Xu WH, Xu Y, Wang J, et al. Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging. 2019;11(17):6999–7020. doi: 10.18632/aging.102233
   PubMedGoogle Scholar
• Liu J, Meng H, Nie S, et al. Identification of a prognostic signature of epithelial ovarian cancer based on tumor immune microenvironment exploration. Genomics. 2020;112(6):4827–4841. doi: 10.1016/j.ygeno.2020.08.027
   PubMed Web of Science ®Google Scholar
• Liu J, Chen C, Wang Y, et al. Comprehensive of N1-methyladenosine modifications patterns and immunological characteristics in ovarian cancer. Front Immunol. 2021;12:12. doi: 10.3389/fimmu.2021.746647
   Web of Science ®Google Scholar
• Gou Q, Liu Z, Xie Y, et al. Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation. Front Pharmacol. 2022;13:995555. doi: 10.3389/fphar.2022.995555
   PubMed Web of Science ®Google Scholar
• Li J, Qiao H, Wu F, et al. A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses. Front Immunol. 2022;13:998140. doi: 10.3389/fimmu.2022.998140
   PubMed Web of Science ®Google Scholar
• Sun J, Shi R, Zhang X, et al. Characterization of immune landscape in papillary thyroid cancer reveals distinct tumor immunogenicity and implications for immunotherapy. Oncoimmunology. 2021;10(1):e1964189. doi: 10.1080/2162402X.2021.1964189
   PubMed Web of Science ®Google Scholar
• Nagendran M, Chen Y, Lovejoy CA, et al. Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies. BMJ. 2020;368:m689. doi: 10.1136/bmj.m689
   PubMed Web of Science ®Google Scholar
• Harding‐Theobald E, Louissaint J, Maraj B, et al. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021;54(7):890–901. doi: 10.1111/apt.16563
   PubMed Web of Science ®Google Scholar
• Tan X, Liang Y, Ye Y, et al. Explainable deep learning-assisted fluorescence discrimination for aminoglycoside antibiotic identification. Anal Chem. 2022;94(2):829–836. doi: 10.1021/acs.analchem.1c03508
   PubMed Web of Science ®Google Scholar
• Krittanawong C, Johnson KW, Rosenson RS, et al. Deep learning for cardiovascular medicine: a practical primer. Eur Heart J. 2019;40(25):2058–2073. doi: 10.1093/eurheartj/ehz056
   PubMed Web of Science ®Google Scholar
• Sarker IH. Deep learning: a comprehensive overview on techniques, taxonomy, applications and research directions. SN Comput Sci. 2021;2(6):420.
   PubMedGoogle Scholar
• Yang JH, Wright SN, Hamblin M, et al. A white-box machine learning approach for revealing antibiotic mechanisms of action. Cell. 2019;177(6):1649–1661 e9. doi: 10.1016/j.cell.2019.04.016
   PubMed Web of Science ®Google Scholar
• Sheu YH. Illuminating the black box: interpreting deep neural network models for psychiatric research. Front Psychiatry. 2020;11:551299. doi: 10.3389/fpsyt.2020.551299
   PubMed Web of Science ®Google Scholar
• Hayashi Y. The right direction needed to develop white-box deep learning in radiology, pathology, and ophthalmology: a short review. Front Robot AI. 2019;6:24. doi: 10.3389/frobt.2019.00024
   PubMed Web of Science ®Google Scholar
• Challen R, Denny J, Pitt M, et al. Artificial intelligence, bias and clinical safety. BMJ Qual Saf. 2019;28(3):231–237. doi: 10.1136/bmjqs-2018-008370
   PubMed Web of Science ®Google Scholar
• Rabbani M, Kanevsky J, Kafi K, et al. Role of artificial intelligence in the care of patients with nonsmall cell lung cancer. Eur J Clin Invest. 2018;48(4). doi: 10.1111/eci.12901
   PubMed Web of Science ®Google Scholar
• Zech JR, Badgeley MA, Liu M, et al. Variable generalization performance of a deep learning model to detect pneumonia in chest radiographs: a cross-sectional study. PLoS Med. 2018;15(11):e1002683. doi: 10.1371/journal.pmed.1002683
   PubMed Web of Science ®Google Scholar
• Reel PS, Reel S, Pearson E, et al. Using machine learning approaches for multi-omics data analysis: a review. Biotechnol Adv. 2021;49:107739.
   PubMed Web of Science ®Google Scholar
• Feng L, Liu Z, Li C, et al. Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. Lancet Digital Health. 2022;4(1):e8–e17. doi: 10.1016/S2589-7500(21)00215-6
   PubMedGoogle Scholar